IRCCS Azienda Ospedaliero - Universitaria di Bologna
Bologna, 40138, Italy
Location status: Recruiting
Location contact
Rocco Maurizio Zagari, MD
CONTACT
Rozzo Maurizio Zagari, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06777017
The study aims to assess whether there is an association between hepatic and splenic elastography values and the risk of HCC recurrence after treatment with RFA
Interested in participating?
Request Info18 year and older
All sexes
Observational
Bologna, 40138, Italy
Location status: Recruiting
Rocco Maurizio Zagari, MD
CONTACT
Rozzo Maurizio Zagari, MD
PRINCIPAL_INVESTIGATOR
The primary objective of the study will be to assess whether there is an association between hepatic and splenic elastography values and the risk of HCC recurrence after treatment with RFA. Secondary objectives, however, will be to test whether hepatic and splenic elastography values have an association with overall and HCC-related survival and with the risk of decompensation after treatment with RFA; further secondary objective will be to evaluate the association between non-invasive biochemical tests and the risk of HCC recurrence after treatment with RFA. The population will consist of hepatopathic patients with HCC who are candidates for treatment with RFA and who are referred to the coordinating center "U.O.C. of Gastroenterology and Digestive Endoscopy" of IRCSS Azienda Ospedaliero-Universitaria, Policlinico di S.Orsola and the Participating Center "U.O. of Gastroenterology," Azienda Ospedaliero-Universitaria Integrata di Modena.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 12 months
The primary objective of the study will be to assess whether there is an association between hepatic and splenic elastography values and the risk of HCC recurrence after treatment with RFA
Contact information is provided by the study sponsor or research team.
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Other
Acronym: ELASTORFA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07521852
Adenocarcinoma, Carcinoma
Fuzhou, Fujian, China
View Trial DetailsNCT07351669
Adenocarcinoma, CT
Nanjing, China
View Trial DetailsNCT07610551
Adenocarcinoma, Carcinoma
Xi’an, Shanxi, China
View Trial DetailsNCT07560488
Adenocarcinoma, Carcinoma
Tianjin, Tianjin Municipality, China
View Trial Details